Eastern Health - Box Hill Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chan, Peter T
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
Litton, Ed
BoneZone, NCT04608630 / ACTRN12621000085875p: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
2
450
RoW
Denosumab 60 MG/ML, Prolia, Xgeva, Zoledronic Acid 5Mg/Bag 100Ml Inj, Zometa, Reclast, Aclasta, Sodium Chloride 0.9% or 5% Dextrose Intravenous, Saline, Placebo, Sodium Chloride 0.9% Injection
Australian and New Zealand Intensive Care Research Centre, Department of Health
Critical Illness, Osteoporosis
02/27
02/27
BALANCE, NCT03005145: Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Completed
N/A
3622
Europe, Canada, US, RoW
7 days of adequate antibiotic treatment, 14 days of adequate antibiotic treatment.
Sunnybrook Health Sciences Centre
Bacteremia, Intensive Care, Critically Ill, Sepsis, Mortality, Antimicrobial
05/23
08/23

Download Options